Primary aldosteronism (PA) is a secondary form of hypertension defined by an autonomous aldosterone overproduction, which is caused in most cases by adrenocortical adenoma or bilateral adrenal hyperplasia. Recently published studies from various geographical populations reported significantly higher prevalence of PA in hypertensive patients than previously accepted 1 -a recent Italian PAPY (PA Prevalence in Italy) study reported a prevalence of 11% in a nonselected population. 2 We have previously shown that PA is the most frequent form of secondary hypertension in patients admitted to our Hypertension Unit with a considerably high (19%) prevalence in moderate to severe hypertension. 3 Retrospective studies showed that subjects with PA might be at higher cardiovascular risk than patients with essential hypertension (EH). 4, 5 Patients with PA present more frequently with increased left ventricular mass, significant impairment of left ventricular diastolic filling, 6 higher urine albumin excretion, 7 increased intima-media thickness of the common carotid artery, 8 and impaired diurnal blood pressure (BP) variation 9 in comparison with EH.
articles Primary aldosteronism (PA) is a secondary form of hypertension defined by an autonomous aldosterone overproduction, which is caused in most cases by adrenocortical adenoma or bilateral adrenal hyperplasia. Recently published studies from various geographical populations reported significantly higher prevalence of PA in hypertensive patients than previously accepted 1 -a recent Italian PAPY (PA Prevalence in Italy) study reported a prevalence of 11% in a nonselected population. 2 We have previously shown that PA is the most frequent form of secondary hypertension in patients admitted to our Hypertension Unit with a considerably high (19%) prevalence in moderate to severe hypertension. 3 Retrospective studies showed that subjects with PA might be at higher cardiovascular risk than patients with essential hypertension (EH). 4, 5 Patients with PA present more frequently with increased left ventricular mass, significant impairment of left ventricular diastolic filling, 6 higher urine albumin excretion, 7 increased intima-media thickness of the common carotid artery, 8 and impaired diurnal blood pressure (BP) variation 9 in comparison with EH.
Aldosterone affects arteriolar vasoactive tone and sodium homeostasis. Recent studies in vascular smooth muscle cell cultures and animal experiments demonstrated that aldosterone contributed substantially to the accumulation of different types of collagen fibers and growth factors. 10, 11 Research has also focused on the role of aldosterone in the changes of aortic collagen accumulation using various pharmacological interventions. Spironolactone prevented the development of aortic fibrosis in spontaneously hypertensive rats. 12 Aldosterone administered to uninephrectomized Sprague-Dawley rats fed with high sodium diet increased carotid arterial stiffness in association with aortic fibronectin accumulation. This effect was independent of the wall stress, as shown by comparison with normotensive controls and eplerenone reversed these vascular changes. 13 In exogenous hyperaldosteronism in rat, aldosterone caused myocardial collagen and arterial fibronectin accumulation, the latter being responsible for increased intrinsic carotid stiffness. Eplerenone prevented Background Aldosterone has been shown to substantially contribute to the accumulation of different types of collagen fibers and growth factors in the arterial wall, which increase wall stiffness. We previously showed that arterial wall stiffness is increased in primary aldosteronism (PA) independently of concomitant hypertension. this study was aimed at assessing the effects of specific treatment of PA on the arterial stiffness.
Methods twenty-nine patients with confirmed PA (15 with aldosterone-producing adenoma treated by unilateral laparoscopic adrenalectomy, 14 treated with spironolactone (mainly idiopathic aldosteronism) were investigated by Sphygmocor applanation tonometer (using measurement of carotid-femoral pulse wave velocity (PWV) and augmentation index (AI)) at the time of the diagnosis and then ~1 year after the specific treatment. results the office blood pressure (bP) decreased from 167 ± 18/96 ± 9 to 136 ± 12/80 ± 7 mm Hg after adrenalectomy (P = 0.001), and from 165 ± 21/91 ± 13 to 151 ± 22/88 ± 8 mm Hg (not significant (n.s.)) on spironolactone. the mean 24-h bP decreased from 150 ± 18/93 ± 11 mm Hg to 126 ± 17/80 ± 10 mm Hg after adrenalectomy (P < 0.01), and from 155 ± 16/94 ± 12 to 139 ± 18/88 ± 8 mm Hg (n.s.) on spironolactone. the PWV significantly decreased after surgery from 9.5 ± 2.7 m/s to 7.6 ± 2 m/s (P = 0.001), and the AI (recalculated for heart rate 75/min) decreased significantly from 27 ± 10 to 19 ± 9% (P < 0.01). on the other hand, we did not find significant change of arterial stiffness indices in patients treated with spironolactone (PWV: 9.3 ± 1.6 m/s vs. 8.8 ± 1.3 m/s (n.s.); AI: 25 ± 9% vs. 25 ± 8% (n.s.)).
conclusions Surgical but not conservative treatment of PA led to a significant decrease of bP and arterial stiffness parameters. articles Arterial Stiffness in Primary Aldosteronism both cardiac and arterial effects but did not reduce consistently systolic BP. 14 There are only few data dealing with the aldosterone effect on vascular changes in humans. 15, 16 The treatment of EH with aldosterone antagonist spironolactone was able to reduce significantly the augmentation index (AI) and pulse wave velocity (PWV). 16 Positive correlations were found between the aldosterone-to-renin ratio and AI, but not between aldosteroneto-renin ratio and PWV. Pronounced fibrosis was detected in small resistance arteries of patients with PA in comparison to BP-matched patients with EH. 17 In our previous study, patients with PA had increased aortic wall stiffness when compared to EH patients. 18 Our study was thus aimed at comparing arterial stiffness in patients with PA by use of central aortic AI (derived from the radial artery pulse wave) and carotid-femoral PWV before and after the specific treatment (adrenalectomy or spironolactone).
Methods
Study population. Overall, 29 patients with PA were studied. Fifteen patients (8 males), aged 47 ± 13 years, underwent laparoscopic adrenalectomy for unilateral adrenal aldosterone-producing adenoma (confirmed before surgery by adrenal venous sampling (AVS) in most patients and then by normalization of plasma aldosterone, plasma renin activity (PRA) and histology) and the remaining 14 patients (8 males), aged 54 ± 9 years, were treated with spironolactone due to bilateral adrenal hyperplasia or unknown subtype of PA (refusal of further investigation, age 65 and more, unsuccessful AVS).
The initial examination of subjects was performed at the time of the diagnosis of PA after discontinuation of their usual antihypertensive therapy. Patients were switched to an α-blocker (doxazosine) and/or slow-release verapamil at least 14 days before the admission to eliminate the interference of other antihypertensive drugs with the renin-angiotensin-aldosterone system. The second examination was performed 1 year after the adrenalectomy (1.1 ± 0.2 years) and after at least 1 year (1.5 ± 0.5 years) of treatment with spironolactone (42 ± 22 mg/ day, range 25-100 mg/day). The dose of spironolactone was up-titrated to achieve target BP control, but was limited by frequent side effects (mostly gynecomastia or menstrual cycle irregularity). Many of the subjects on spironolactone were treated with other antihypertensives, particularly slowrelease verapamil (93%), hydrochlorothiazide (71%), and amiloride (36%) to achieve better BP control. The use of other antihypertensive drugs was rare (one patient β-blocker and one angiotensin-receptor blocker). Most of the patients who underwent adrenalectomy (9) did not receive any antihypertensive treatment after surgery.
Laboratory tests. The screening for the diagnosis of PA was based on an elevated aldosterone-to-renin ratio ≥40 ((ng/dl)/ (ng/ml/h)) when PRA and aldosterone levels were measured after 2-h upright position, suppressed PRA (≤0.7 ng/ml/h) and elevated plasma aldosterone (≥15 ng/dl). The diagnosis of PA was confirmed by the absence of plasma aldosterone suppression after saline infusion (plasma aldosterone ≤7 ng/ dl). 19, 20 AVS was used in 10 of 15 patients in the surgically treated group. The remaining five were referred directly to surgery because of a large tumor (over 2 cm), young age, and absence of aldosterone stimulation during postural testing. The group treated with spironolactone consisted of six patients who refused AVS, three in whom AVS proved idiopathic hyperaldosteronism, and five in whom the results of AVS were inconclusive or nonselective and who refused repeated AVS. We used AVS criteria according to a previously published study 21 : success = adrenal vein/inferior vena cava cortisol gradient >2; lateralization was considered to be present when the aldosterone/cortisol ratio on one side was greater than four times contralateral.
All hormonal tests were performed by radioimmunoanalysis using commercially available kits (Immunotech, Beckman Coulter Company, Prague, Czech Republic). Other biochemical parameters were analyzed in the institutional central laboratory.
Pulse wave analysis. All subjects were studied after an overnight fasting in a quiet room. After 15 min at rest in supine position, the pulse wave analysis and PWV measurements were performed by the applanation tonometer SphygmoCor (AtCor Medical, West Ryde, Australia).
Pulse wave was measured at radial artery and the aortic pulse wave was derived by means of generalized transfer function. The aortic waveform was calibrated using a single simultaneous measurement of brachial artery BP by an oscillometric sphygmomanometer-(Dinamap, Critikon, Tampa, FL). The aortic (or central) AI was calculated as the ratio of the pressure difference (ΔP) between the shoulder of the wave and the peak systolic pressure to pulse pressure according to the formula AI = (ΔP/(systolic BP−diastolic BP)) × 100 (ref. 22) . AI values were adjusted for heart rate of 75 beats/min using a SphygmoCor built-in algorithm. 23 In previous large study, the generalized transfer function utilized by SphygmoCor provided acceptable estimate of the ascending aortic systolic, diastolic, and pulse pressures under different conditions. 23 A high level of repeatability and reproducibility of SphygmoCor pulse wave measurements has been established for various patient groups. 24, 25 Aortic PWV was assessed by the time difference between pulse wave upstrokes, which were consecutively measured at right carotid artery and right femoral artery and aligned by ECG-based trigger. The "percentage pulse height algorithm" was used to locate the "foot" of the pulse waves.
Oscillometric Spacelabs 90207 device (Spacelabs Medical, Redmond, WA) was used for 24-h ambulatory BP monitoring. The measurements were set at 20-min interval during daytime (6:00-22:00) and 30-min interval during nighttime 22:00-6:00).
Statistical analysis. The statistical analysis was performed by STATISTICA software (Statsoft, Tulsa, OK). Normally distributed data were described by mean ± s.d.). Continuous variables with clearly nonnormal distributions (Shapiro-Wilks W-test) were described as medians (interquartile range).
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The paired measurements (before/after treatment) were compared using either t-test for dependent samples or Wilcoxon matched pairs test, as appropriate. The difference between two treatment groups was analyzed by t-test for independent samples. Pearson's correlation analysis was used to assess the relationship between the PWV or AI and other clinical parameters as well as the relationship between their treatment-induced changes. Spearman's correlation was used for nonnormally distributed indices. Multiple regression analysis was used to adjust the observed change in PWV and AI for all relevant covariates (i.e., significantly correlated with PWV and AI). Specifically, the general regression model was used with the difference in PWV and AI before/after treatment as a dependent variable and treatment group as an independent categorical variable. All univariatelly significant clinical covariates (shown in detail in Results), their baseline values and/or changes due to the intervention, entered the model as independent continuous variables. P < 0.05 was considered significant.
results
The baseline characteristics of the studied groups and the effects of the treatment are shown in Table 1 .
As expected, we observed a significant decrease in plasma sodium, increase in potassium, normalization of aldosterone levels and PRA after surgery and increase of aldosterone levels and PRA after spironolactone treatment.
Positive family history of hypertension was noted in 60% patients in surgically treated group and in 64% patients in the spironolactone group (not significant (n.s.)).
On average, 3.3 ± 0.8 antihypertensive drugs were used in the spironolactone group and 1.0 ± 1.3 drugs after adrenalectomy (P < 0.001).
The PWV significantly decreased after surgery from 9.5 ± 2.7 m/s to 7.6 ± 2 m/s (P = 0.001), and also the AI (recalculated for heart rate 75/min) decreased significantly from 27 ± 10% to 19 ± 9% (P < 0.01). On the other hand, we did not find significant change (only a trend to PWV lowering) of arterial stiffness indices in patients treated with spironolactone (PWV: 9.3 ± 1.6 m/s vs. 8.8 ± 1.3 m/s (n.s.); AI: 25 ± 9% vs. 25 ± 8% (n.s.)) (Figure 1) .
Directly measured BP parameters and derived central BP indices before and after treatment are summarized in Table 2 . Significant decrease of BP variables was observed only in the group of surgically treated patients.
The PWV (before treatment) was significantly correlated with age (r = 0.53, P = 0.003), systolic BP (r = 0.47, P = 0.01), 24-h systolic BP (r = 0.51, P = 0.005), plasma fasting glucose (r = 0.47, P = 0.01), plasma sodium (r = 0.54, P = 0.003), and potassium (r = 0.39, P = 0.036). The AI (before treatment) was significantly correlated only with diastolic BP (r = 0.48, P = 0.09).
The difference in PWV and AI before/after treatment correlated significantly only with the decrease in systolic BP (r = 0.50, P = 0.006; r = 0.58, P = 0.001, respectively) and the decrease in diastolic BP (r = 0.58, P = 0.001; r = 0.54, P = 0.002, respectively). No significant correlation was found between the change in arterial stiffness indices and the treatment-induced change in plasma sodium, potassium, aldosterone, and PRA.
Changes in office SBP and DBP were tested separately because of their tight colinearity. For the same reason, and because of missing relationship with PWV and AI, the ambulatory BP measurements were not used as covariates.
In the general regression model with treatment group, change in systolic or diastolic BP, baseline fasting glucose, and age as independent variables, the surgical treatment was borderline significantly associated with the decrease of PWV (P = 0.06 and P = 0.06 when adjusted for systolic and diastolic BP, respectively). In the regression model with treatment group and change in systolic or diastolic BP as independent variables, the surgical treatment was almost significantly associated with the decrease of AI (P = 0.053 and P = 0.057 when adjusted for systolic and diastolic BP, respectively). In addition, Figure 2 illustrates the dominant effect of treatment-induced change in systolic/diastolic BP on the change in indices of arterial stiffness and suggests that surgical treatment might have more beneficial effect on arterial stiffness independently of BP lowering when compared to treatment with spironolactone.
discussion
We demonstrated that surgical treatment of PA led to a significant BP decrease that was accompanied by a significant decrease in arterial stiffness. Arterial stiffness depends in particular on BP and age. 26 Treatment by various antihypertensive drugs usually leads to an improvement of arterial stiffness indices, but it is still unclear whether this reduction is attributable only to BP lowering or to additional effects on the blood vessel wall. 27 In our study, change in both PWV and AI after intervention was clearly related to the decrease of office SBP and DBP. However, in multivariate analysis based predominantly on changes after intervention, the surgical treatment was a consistent, even if statistically borderline, determinant of higher decrease of PWV and AI. This means that other pathogenetic mechanisms, apart from the decrease in BP (e.g., absence of excess aldosterone after surgery in contrast to further increase of aldosterone under spironolactone with activation of nongenomic mechanisms of action), may play an important role.
In contrast, no significant improvement in arterial stiffness was observed after medical treatment with spironolactone. One possible explanation is that this treatment strategy was not sufficient to decrease BP significantly. It may be caused by the relatively low dose, which was limited due to frequent dosedependent side effects, predominantly gynecomastia. 28 In a recent study, therefore, spironolactone treatment was discontinued in 28% of patients with PA. 29 In our study, even >60% of men reported painful gynecomastia with doses of 50-100 mg/ day. The alternative agent, eplerenone, is free from these adverse side effects. Few data are, however, available about its effects on BP and its recommended dose in PA. Moreover, eplerenone is not yet approved for treatment of hypertension in our country and in some other European countries.
Surprisingly, despite the use of therapy in addition to spironolactone (slow-release verapamil and/or thiazide and/ or amiloride diuretics) in most patients, the BP fall was still markedly less than that of patients treated surgically.
The increase observed in plasma aldosterone and PRA in the spironolactone group, possibly strengthened by use articles
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of thiazide diuretics, may also have led to the "superimposition" of secondary on top of PA. Consequently, nongenomic pathways of aldosterone action, which cannot be prevented by spironolactone, could be activated and influence arterial stiffening. 30, 31 For example, a direct vasoconstrictive effect on the resistant arteries was documented in healthy volunteers by forearm blood flow measurement during aldosterone infusion. 32 Furthermore, the increase of aldosterone induced by spironolactone can trigger a vicious circle where the amount of spironolactone prescribed could be insufficient to block the mineralocorticoid receptor sufficiently from attack by high plasma aldosterone levels. Another contributing factor may be a possible delayed effect of spironolactone treatment on the improvement in arterial stiffness indices. Significant decreases of left ventricular wall thickness and mass were observed in patients treated with surgical excision of an aldosterone-producing tumor after 1 year of follow-up, but not in those undertaking medical therapy. 6 In a recent study, the effects of adrenalectomy on the thickness of the left ventricular wall were already discernible after 1 year following surgery in the same way as decreased arterial stiffness in our study, whereas the spironolactone group revealed significant improvement later (6 years after the start of treatment), partially independent of BP changes. 33 Therefore, it might be suggested that 1-year lasting treatment with spironolactone may not have a significant effect on arterial stiffness, whereas prolonged follow-up would lead to significant results. Because data on BP control during the first year of spironolactone treatment were lacking in the study quoted, 33 one could speculate about a relatively delayed onset of spironolactone action, which might lead to inadequate control of hypertension during the first 1-2 months of treatment. The dose of spironolactone used (50-300 mg, on average 121 mg daily) was significantly higher than in our study, and would be intolerable for most of our patients due to the frequent side effects (see above).
The lack of correlation between the decrease in aldosterone and the increase in PRA after surgery and arterial stiffness indices in our study is similar to the findings of another study, which reported the absence of a direct correlation between vascular stiffness and plasma aldosterone. 34 Two explanations can be proposed. First, hormone levels assessed during investigation (drugs washout period) may not correspond to the chronic impact of hyperaldosteronism before the diagnosis of PA. Second, plasma aldosterone levels may not reflect the local production of aldosterone in the vascular wall. This hypothesis is supported by the finding of a 17-fold higher concentration of aldosterone in cardiac tissue compared with plasma. 35 Among baseline parameters, only age and fasting glucose were identified (and included) as relevant confounders of PWV in multivariate analysis. Patients in the spironolactonetreated group were also somewhat (but not significantly) older than patients treated surgically. Nevertheless, even after taking into account these confounding factors, the superiority of the surgical treatment over spironolactone in improving arterial stiffness was still evident.
In our study, we did not detect any between group differences in family history of hypertension, which may be helpful in predicting the outcome of surgery. 36 No significant differences were found between both groups relative to the duration of hypertension, which may be a predictive factor in outcome of adrenalectomy. 36 We can only speculate that longer lasting hypertension in the spironolactonetreated group may affect arterial stiffness, causing more profound vascular changes.
Limitations of the study: When selecting patients with PA, the aldosterone-to-renin ratio limit of 40 (ng/dl)/(ng/ml/h) used in our study (similar to that used in the PAPY study) 2 for the screening could cause us to overlook some aldosteroneproducing adenomas. The saline suppression test as a confirmation test is only moderately accurate for detecting PA and false-positive and false-negative results are to be expected. 37 We may also have misdiagnosed some aldosterone-producing adenomas as idiopathic aldosteronism because of the strict AVS criteria for identifying aldosterone-producing adenomas. We could not perform AVS on patients who refused this invasive method and we did not use AVS in all cases as mentioned in detail above. All these limitations had, by our opinion, only a partial impact on our study, because the aim was not to assess the discrimination value of different diagnostic tests. On the contrary, we have investigated the possible difference/similarity in the effect of definite removal of the source of aldosterone excess (adrenalectomy for unilateral aldosterone-producing adenoma with normalization of aldosterone and PRA) as against simply blocking aldosterone receptors by spironolactone in the conservatively treated group concerning arterial stiffness. Our data may thus support surgical treatment over medical treatment based on arterial stiffness improvement.
A relatively low dose of spironolactone, the unavailability of eplerenone (which has not been approved for treatment of hypertension in our country) and a smaller sample of subjects studied are other possible limitations of our study. One may speculate that the present trend toward lowering BP in the spironolactone group would become significant in a larger group of patients.
The main finding of our study is that surgical treatment of PA leads to a significant decrease of BP and arterial wall stiffness, whereas the conservative treatment with spironolactone was inferior to adrenalectomy in decreasing BP and arterial wall stiffness. To minimize the high cardiovascular risk of these patients, surgical treatment should be the preferred mode of treatment in all patients with unilateral forms of PA.
